

Executive Secretary at one of the following addresses:

1. *Submissions via Express/Package Delivery Services*: Foreign-Trade Zones Board, U.S. Department of Commerce, Franklin Court Building—Suite 4100W, 1099 14th Street, NW., Washington, DC 20005; or

2. *Submissions via the U.S. Postal Service*: Foreign-Trade Zones Board, U.S. Department of Commerce, FCB—Suite 4100W, 1401 Constitution Avenue, NW., Washington, DC 20230.

The closing period for their receipt is August 23, 2004. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period (to September 7, 2004).

A copy of the application and accompanying exhibits will be available during this time for public inspection at address Number 1 listed above, and at the U.S. Department of Commerce Export Assistance Center, 600 Superior Avenue East, Suite 700, Cleveland, OH 44114.

Dated: June 10, 2004.

Dennis Puccinelli,

Executive Secretary.

[FR Doc. 04–13987 Filed 6–21–04; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Order No. 1338]

Approval of Manufacturing Authority Foreign-Trade Zone 37, Minolta Advance Technology, Inc. (Toner Products); Goshen, NY

Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a–81u), the Foreign-Trade Zones Board (the Board) adopts the following Order:

Whereas, Orange County, New York, grantee of Foreign-Trade Zone 37, on behalf of Minolta Advance Technology, Inc., has requested authority to manufacture bulk toner, toner cartridges for computer printers and copiers, and remanufacture toner cartridges, under FTZ procedures within FTZ 37–Site 7;

Whereas, notice inviting public comment has been given in the **Federal Register** (68 FR 57405, 10/3/03);

Whereas, the application was amended 5/13/04 to withdraw HTSUS categories: 5807.10, 5906.10.0000 and 8524, from the requested scope of authority for imported materials;

Whereas, pursuant to section 400.32(b)(1) of the FTZ Board regulations (15 CFR 400), the Secretary

of Commerce's delegate on the FTZ Board has the authority to act for the Board in making decisions regarding manufacturing activity within existing zones when the proposed activity is the same, in terms of products involved, to activity recently approved by the Board and similar in circumstances (15 CFR 400.32(b)(1)(i)); and,

Whereas, the Board adopts the findings and recommendations of the examiner's report, and finds that the requirements of the FTZ Act and the Board's regulations are satisfied, and that approval of the request, as amended, is in the public interest;

Now, therefore, the Board hereby orders:

The application, as amended, on behalf of Minolta Advance Technology, Inc., to manufacture bulk toner, toner cartridges for computer printers and copiers, and remanufacture toner cartridges, under zone procedures within FTZ 37–Site 7, is approved, subject to the FTZ Act and the Board's regulations, including Section 400.28.

Signed at Washington, DC, this 14th day of June 2004.

James J. Jochum,

Assistant Secretary of Commerce for Import Administration, Alternate Chairman, Foreign-Trade Zones Board.

[FR Doc. 04–13986 Filed 6–21–04; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–570–853]

Bulk Aspirin From the People's Republic of China: Final Results of 2002/2003 Antidumping Duty Administrative Review and Final Determination To Revoke the Order In Part

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of final results of antidumping duty administrative review and revocation of the order in part.

SUMMARY: On April 8, 2004, the Department of Commerce published the preliminary results of the 2002/2003 administrative review of the antidumping duty order on bulk aspirin from the People's Republic of China with respect to Shandong Xinhua Pharmaceutical Co., Ltd. This review covers sales of bulk aspirin to the United States during the period July 1, 2002, through June 30, 2003. Based on our analysis of comments received, we conclude that the final results do not

differ from the preliminary results of review, in which we found that the respondent made sales in the United States at prices not below normal value. We also find that the antidumping duty order with respect to Shandong Xinhua Pharmaceutical Co., Ltd. should be revoked.

DATES: *Effective Date:* June 22, 2004.

FOR FURTHER INFORMATION CONTACT: Julie Santoboni or Scott Holland, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th and Constitution Avenue, NW., Washington, DC 20230; telephone (202) 482–4194 or (202) 482–1279, respectively.

SUPPLEMENTARY INFORMATION:

Background

Since the publication of the preliminary results of this review (*Bulk Aspirin from the People's Republic of China: Preliminary Results of 2002/2003 Antidumping Duty Administrative Review And Notice Of Intent To Revoke Order In Part*, 69 FR 18520 (April 8, 2004) (“*Preliminary Results*”)), the following events have occurred:

On May 10, 2004, the Department of Commerce (“the Department”) issued the verification report for Shandong Xinhua Pharmaceutical Co., Ltd. (“Shandong”). See Memorandum to the File, “Shandong Xinhua Pharmaceutical Co., Ltd. Verification Report,” dated May 10, 2004. This report is on file in the Central Records Unit, Room B–099 of the main Department Building (“CRU”).

On May 10, 2004, Perrigo Company (“Perrigo”), an interested party, and Shandong submitted case briefs. No rebuttal briefs were submitted, nor was a public hearing held.

Scope of the Order

The product covered by the order is bulk acetylsalicylic acid, commonly referred to as bulk aspirin, whether or not in pharmaceutical or compound form, not put up in dosage form (tablet, capsule, powders or similar form for direct human consumption). Bulk aspirin may be imported in two forms, as pure ortho-acetylsalicylic acid or as mixed ortho-acetylsalicylic acid. Pure ortho-acetylsalicylic acid can be either in crystal form or granulated into a fine powder (pharmaceutical form). This product has the chemical formula (C₉H₈O₄). It is defined by the official monograph of the United States Pharmacopoeia 23 (“USP”). It is currently classifiable under the *Harmonized Tariff Schedule of the United States* (“HTSUS”) subheading 2918.22.1000.